Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod and UV-B dermal inflammatory challenge study for complement activation in healthy volunteers
NL-OMON50971Completed
- Sponsor
- Centre for Human Drug Research
- Start
- Feb 2021
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of imiquimod (2 arms), sponsored by Centre for Human Drug Research. Primary endpoints: Complement factors in skin biopsies following imiquimod challenge and Complement factors in skin biopsies following UV-B challenge. Started Feb 2021; status: completed.
02
Drugs
imiquimod
Beyond the preview
Go deeper on NL-OMON50971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50971.